BioCentury
ARTICLE | Clinical News

Synavive: Development discontinued

September 17, 2012 7:00 AM UTC

Zalicus discontinued development of Synavive after the double-blind, international Phase IIb SYNERGY trial in 259 patients with moderate to severe RA showed that the compound missed the secondary endpoint of reducing DAS28-CRP scores from baseline to week 12 vs. 2.7 mg prednisolone, the active glucocorticoid component of Synavive (0.9 vs. 1.125 points). Synavive did meet the primary endpoint of reducing DAS28-CRP scores from baseline to week 12 vs. placebo (0.5 points). All patients remained on stable dose DMARD therapy for the 6 weeks leading up to and throughout the study. Patients received once-daily placebo, Synavive, prednisolone, dipyridamole or prednisone. ...